Share Price and Basic Stock Data
Last Updated: December 10, 2025, 8:59 pm
| PEG Ratio | 5.85 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
FDC Ltd, a prominent player in the Indian pharmaceuticals sector, has shown a commendable trajectory in revenue growth. For the fiscal year ending March 2025, the company reported sales of ₹2,108 Cr, up from ₹1,943 Cr in the previous year. This upward trend reflects a consistent demand for its pharmaceutical products, particularly as the company adapts to changing healthcare needs. The quarterly sales figures also reveal a pattern of recovery post-pandemic, with the most recent quarter ending June 2025 standing at ₹648 Cr, showcasing a robust year-on-year growth. However, it’s noteworthy that the operating profit margin (OPM) has fluctuated, declining from 17% in FY 2022 to 15% in FY 2025, indicative of rising costs or pricing pressures that could affect future profitability. Overall, the revenue trajectory appears strong, but investors should remain alert to the underlying factors influencing margins.
Profitability and Efficiency Metrics
FDC Ltd’s profitability metrics present a mixed picture. The net profit for FY 2025 was reported at ₹267 Cr, a decline from ₹305 Cr in the previous year, which raises concerns about its ability to maintain profit levels amidst rising operational expenses. The company’s return on equity (ROE) stood at 11.69%, which, while decent, is below the industry average, suggesting that shareholder returns could be more robust. The interest coverage ratio (ICR) is notably high at 92.13x, indicating that FDC Ltd comfortably manages its interest obligations, a strong point for potential investors. However, the cash conversion cycle (CCC) of 103 days could suggest inefficiencies in managing receivables and inventory, which, if not addressed, might hinder cash flow and operational agility in the long run. Balancing profitability with operational efficiency will be crucial for sustaining investor confidence.
Balance Sheet Strength and Financial Ratios
The balance sheet of FDC Ltd reflects a solid foundation, with total reserves amounting to ₹2,265 Cr against minimal borrowings of ₹21 Cr. This low debt level positions the company well for future investments without the burden of heavy interest payments. The current ratio stands at 3.01, indicating that the company has ample liquidity to cover short-term liabilities, which is a positive sign for risk-averse investors. Additionally, the price-to-book value (P/BV) ratio of 2.81x suggests that the stock is trading at a premium compared to its book value, which could imply market confidence in the company’s growth prospects. However, the declining return on capital employed (ROCE) at 15.37% raises some caution flags, as it indicates that the efficiency of capital utilization might be waning. A focused approach on enhancing capital returns could bolster the balance sheet’s robustness further.
Shareholding Pattern and Investor Confidence
The shareholding structure of FDC Ltd reveals significant promoter confidence, with promoters holding 69.66% of the equity. This substantial stake can be reassuring for retail investors, as it indicates a strong commitment to the company’s long-term vision. Meanwhile, foreign institutional investors (FIIs) hold a modest 2.43%, while domestic institutional investors (DIIs) account for 6.81%. The public shareholding has gradually increased to 21.10%, reflecting a growing interest from retail investors. However, the recent decline in FII percentages could indicate some caution from foreign investors regarding market conditions or company-specific factors. As retail participation grows, the company must ensure transparency and effective communication with its shareholders to maintain and build investor confidence.
Outlook, Risks, and Final Insight
Looking ahead, FDC Ltd faces a dual-edged sword of opportunities and challenges. On one hand, the company is well-positioned to capitalize on the expanding Indian pharmaceutical market, bolstered by a strong product portfolio and low debt levels. On the other hand, potential risks include fluctuating margins due to rising costs and the need for operational efficiencies to improve cash flow. The decline in net profit and ROE could also be red flags for investors seeking stable returns. As the healthcare landscape evolves, FDC Ltd must navigate regulatory changes and competitive pressures effectively. For retail investors, understanding these dynamics is crucial. While the stock offers potential growth, the associated risks warrant careful consideration, especially in a sector marked by volatility. Staying informed about the company’s strategic initiatives and market trends will be key to making informed investment decisions.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of FDC Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 142 Cr. | 113 | 239/84.3 | 31.4 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,177 Cr. | 383 | 479/192 | 86.5 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.4 Cr. | 43.6 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 45.3 Cr. | 30.9 | 31.0/17.0 | 108 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,300.00 Cr | 1,152.20 | 52.34 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 495 | 445 | 409 | 435 | 536 | 486 | 458 | 462 | 638 | 514 | 464 | 492 | 648 |
| Expenses | 417 | 378 | 360 | 386 | 414 | 410 | 374 | 406 | 492 | 444 | 417 | 438 | 508 |
| Operating Profit | 78 | 67 | 49 | 49 | 122 | 76 | 84 | 56 | 147 | 70 | 47 | 54 | 140 |
| OPM % | 16% | 15% | 12% | 11% | 23% | 16% | 18% | 12% | 23% | 14% | 10% | 11% | 22% |
| Other Income | 19 | 13 | 18 | 7 | 29 | 27 | 25 | 20 | 28 | 35 | 19 | 16 | 36 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 11 | 14 | 13 | 16 | 15 |
| Profit before tax | 87 | 69 | 57 | 45 | 141 | 93 | 98 | 65 | 163 | 90 | 51 | 53 | 160 |
| Tax % | 19% | 25% | 28% | 32% | 22% | 25% | 19% | 29% | 27% | 20% | 28% | 27% | 24% |
| Net Profit | 71 | 52 | 41 | 31 | 110 | 70 | 79 | 46 | 119 | 72 | 37 | 39 | 121 |
| EPS in Rs | 4.26 | 3.12 | 2.46 | 1.85 | 6.62 | 4.29 | 4.87 | 2.84 | 7.31 | 4.42 | 2.28 | 2.38 | 7.45 |
Last Updated: August 20, 2025, 11:00 am
Below is a detailed analysis of the quarterly data for FDC Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 648.00 Cr.. The value appears strong and on an upward trend. It has increased from 492.00 Cr. (Mar 2025) to 648.00 Cr., marking an increase of 156.00 Cr..
- For Expenses, as of Jun 2025, the value is 508.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 438.00 Cr. (Mar 2025) to 508.00 Cr., marking an increase of 70.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 140.00 Cr.. The value appears strong and on an upward trend. It has increased from 54.00 Cr. (Mar 2025) to 140.00 Cr., marking an increase of 86.00 Cr..
- For OPM %, as of Jun 2025, the value is 22.00%. The value appears strong and on an upward trend. It has increased from 11.00% (Mar 2025) to 22.00%, marking an increase of 11.00%.
- For Other Income, as of Jun 2025, the value is 36.00 Cr.. The value appears strong and on an upward trend. It has increased from 16.00 Cr. (Mar 2025) to 36.00 Cr., marking an increase of 20.00 Cr..
- For Interest, as of Jun 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 15.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 16.00 Cr. (Mar 2025) to 15.00 Cr., marking a decrease of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 160.00 Cr.. The value appears strong and on an upward trend. It has increased from 53.00 Cr. (Mar 2025) to 160.00 Cr., marking an increase of 107.00 Cr..
- For Tax %, as of Jun 2025, the value is 24.00%. The value appears to be improving (decreasing) as expected. It has decreased from 27.00% (Mar 2025) to 24.00%, marking a decrease of 3.00%.
- For Net Profit, as of Jun 2025, the value is 121.00 Cr.. The value appears strong and on an upward trend. It has increased from 39.00 Cr. (Mar 2025) to 121.00 Cr., marking an increase of 82.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 7.45. The value appears strong and on an upward trend. It has increased from 2.38 (Mar 2025) to 7.45, marking an increase of 5.07.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 5:22 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 845 | 888 | 994 | 1,013 | 1,074 | 1,089 | 1,341 | 1,331 | 1,525 | 1,784 | 1,943 | 2,108 | 2,118 |
| Expenses | 638 | 690 | 765 | 769 | 841 | 860 | 1,038 | 997 | 1,271 | 1,533 | 1,604 | 1,783 | 1,807 |
| Operating Profit | 207 | 199 | 229 | 243 | 233 | 229 | 304 | 334 | 254 | 251 | 339 | 325 | 311 |
| OPM % | 24% | 22% | 23% | 24% | 22% | 21% | 23% | 25% | 17% | 14% | 17% | 15% | 15% |
| Other Income | 39 | 46 | 39 | 44 | 45 | 42 | 57 | 95 | 76 | 50 | 102 | 91 | 105 |
| Interest | 3 | 2 | 1 | 1 | 1 | 1 | 3 | 3 | 3 | 4 | 4 | 5 | 4 |
| Depreciation | 25 | 39 | 34 | 35 | 35 | 33 | 37 | 38 | 37 | 39 | 40 | 54 | 58 |
| Profit before tax | 218 | 204 | 232 | 252 | 241 | 237 | 320 | 388 | 289 | 258 | 396 | 357 | 354 |
| Tax % | 38% | 27% | 27% | 25% | 28% | 28% | 25% | 22% | 25% | 25% | 23% | 25% | |
| Net Profit | 135 | 148 | 169 | 189 | 174 | 170 | 240 | 301 | 216 | 194 | 305 | 267 | 269 |
| EPS in Rs | 7.61 | 8.33 | 9.48 | 10.60 | 9.95 | 9.74 | 14.03 | 17.85 | 12.82 | 11.70 | 18.75 | 16.39 | 16.53 |
| Dividend Payout % | 30% | 27% | 24% | 21% | 0% | 0% | 6% | 0% | 0% | 0% | 0% | 31% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 9.63% | 14.19% | 11.83% | -7.94% | -2.30% | 41.18% | 25.42% | -28.24% | -10.19% | 57.22% | -12.46% |
| Change in YoY Net Profit Growth (%) | 0.00% | 4.56% | -2.35% | -19.77% | 5.64% | 43.48% | -15.76% | -53.66% | 18.05% | 67.40% | -69.68% |
FDC Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 9% |
| 3 Years: | 11% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 2% |
| 3 Years: | 7% |
| TTM: | -14% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 8% |
| 3 Years: | 18% |
| 1 Year: | -18% |
| Return on Equity | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 13% |
| 3 Years: | 12% |
| Last Year: | 12% |
Last Updated: September 5, 2025, 3:55 am
Balance Sheet
Last Updated: December 10, 2025, 2:39 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 18 | 18 | 18 | 18 | 18 | 18 | 17 | 17 | 17 | 17 | 16 | 16 | 16 |
| Reserves | 827 | 919 | 1,065 | 1,252 | 1,259 | 1,428 | 1,530 | 1,717 | 1,940 | 1,965 | 2,081 | 2,265 | 2,415 |
| Borrowings | 3 | 2 | 1 | 1 | 1 | 1 | 15 | 15 | 32 | 28 | 21 | 21 | 21 |
| Other Liabilities | 211 | 210 | 182 | 197 | 228 | 194 | 250 | 207 | 281 | 333 | 350 | 412 | 433 |
| Total Liabilities | 1,059 | 1,148 | 1,266 | 1,468 | 1,505 | 1,640 | 1,813 | 1,956 | 2,270 | 2,343 | 2,468 | 2,714 | 2,886 |
| Fixed Assets | 284 | 393 | 675 | 678 | 674 | 682 | 674 | 689 | 705 | 699 | 680 | 852 | 842 |
| CWIP | 18 | 29 | 20 | 6 | 13 | 12 | 24 | 19 | 105 | 198 | 261 | 137 | 163 |
| Investments | 417 | 489 | 325 | 491 | 471 | 585 | 665 | 790 | 886 | 806 | 843 | 1,028 | 1,007 |
| Other Assets | 340 | 237 | 246 | 293 | 348 | 360 | 451 | 458 | 575 | 640 | 684 | 698 | 874 |
| Total Assets | 1,059 | 1,148 | 1,266 | 1,468 | 1,505 | 1,640 | 1,813 | 1,956 | 2,270 | 2,343 | 2,468 | 2,714 | 2,886 |
Below is a detailed analysis of the balance sheet data for FDC Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 16.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 16.00 Cr..
- For Reserves, as of Sep 2025, the value is 2,415.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,265.00 Cr. (Mar 2025) to 2,415.00 Cr., marking an increase of 150.00 Cr..
- For Borrowings, as of Sep 2025, the value is 21.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 21.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 433.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 412.00 Cr. (Mar 2025) to 433.00 Cr., marking an increase of 21.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 2,886.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,714.00 Cr. (Mar 2025) to 2,886.00 Cr., marking an increase of 172.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 842.00 Cr.. The value appears to be declining and may need further review. It has decreased from 852.00 Cr. (Mar 2025) to 842.00 Cr., marking a decrease of 10.00 Cr..
- For CWIP, as of Sep 2025, the value is 163.00 Cr.. The value appears strong and on an upward trend. It has increased from 137.00 Cr. (Mar 2025) to 163.00 Cr., marking an increase of 26.00 Cr..
- For Investments, as of Sep 2025, the value is 1,007.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,028.00 Cr. (Mar 2025) to 1,007.00 Cr., marking a decrease of 21.00 Cr..
- For Other Assets, as of Sep 2025, the value is 874.00 Cr.. The value appears strong and on an upward trend. It has increased from 698.00 Cr. (Mar 2025) to 874.00 Cr., marking an increase of 176.00 Cr..
- For Total Assets, as of Sep 2025, the value is 2,886.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,714.00 Cr. (Mar 2025) to 2,886.00 Cr., marking an increase of 172.00 Cr..
Notably, the Reserves (2,415.00 Cr.) exceed the Borrowings (21.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 204.00 | 197.00 | 228.00 | 242.00 | 232.00 | 228.00 | 289.00 | 319.00 | 222.00 | 223.00 | 318.00 | 304.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 26 | 25 | 23 | 27 | 28 | 29 | 34 | 30 | 20 | 25 | 22 | 19 |
| Inventory Days | 116 | 132 | 134 | 148 | 166 | 184 | 180 | 189 | 210 | 183 | 216 | 186 |
| Days Payable | 90 | 94 | 84 | 81 | 101 | 82 | 101 | 68 | 94 | 99 | 103 | 102 |
| Cash Conversion Cycle | 51 | 64 | 72 | 94 | 93 | 131 | 113 | 152 | 135 | 109 | 135 | 103 |
| Working Capital Days | 1 | 11 | 21 | 23 | 29 | 45 | 40 | 48 | 45 | 48 | 53 | 33 |
| ROCE % | 25% | 21% | 22% | 21% | 19% | 17% | 21% | 22% | 15% | 13% | 18% | 16% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Nippon India Small Cap Fund | 4,275,331 | 0.29 | 196.94 | 4,257,262 | 2025-12-08 07:42:13 | 0.42% |
| ICICI Prudential Smallcap Fund | 1,926,874 | 1.03 | 88.76 | 1,509,088 | 2025-12-07 05:36:57 | 27.68% |
| ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 1,197,689 | 0.86 | 55.17 | N/A | N/A | N/A |
| Tata India Pharma & HealthCare Fund | 841,720 | 2.93 | 38.77 | N/A | N/A | N/A |
| ICICI Prudential ESG Exclusionary Strategy Fund | 559,323 | 1.69 | 25.77 | N/A | N/A | N/A |
| ICICI Prudential MNC Fund | 486,581 | 1.3 | 22.41 | N/A | N/A | N/A |
| Bandhan Small Cap Fund | 446,288 | 0.12 | 20.56 | N/A | N/A | N/A |
| ITI Pharma and Healthcare Fund | 70,933 | 1.4 | 3.27 | 69,869 | 2025-12-07 06:36:36 | 1.52% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 16.39 | 18.58 | 11.66 | 12.81 | 17.72 |
| Diluted EPS (Rs.) | 16.39 | 18.58 | 11.66 | 12.81 | 17.72 |
| Cash EPS (Rs.) | 19.69 | 21.19 | 14.03 | 15.01 | 20.08 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 140.11 | 128.81 | 119.43 | 115.89 | 102.72 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 140.11 | 128.81 | 119.43 | 115.89 | 102.72 |
| Revenue From Operations / Share (Rs.) | 129.48 | 119.34 | 107.51 | 90.51 | 78.98 |
| PBDIT / Share (Rs.) | 25.52 | 27.04 | 18.13 | 19.54 | 25.54 |
| PBIT / Share (Rs.) | 22.22 | 24.58 | 15.79 | 17.33 | 23.30 |
| PBT / Share (Rs.) | 21.94 | 24.34 | 15.54 | 17.14 | 22.97 |
| Net Profit / Share (Rs.) | 16.39 | 18.74 | 11.68 | 12.81 | 17.84 |
| NP After MI And SOA / Share (Rs.) | 16.39 | 18.75 | 11.70 | 12.82 | 17.85 |
| PBDIT Margin (%) | 19.70 | 22.65 | 16.86 | 21.58 | 32.33 |
| PBIT Margin (%) | 17.15 | 20.60 | 14.68 | 19.14 | 29.49 |
| PBT Margin (%) | 16.94 | 20.39 | 14.45 | 18.94 | 29.08 |
| Net Profit Margin (%) | 12.65 | 15.70 | 10.86 | 14.14 | 22.59 |
| NP After MI And SOA Margin (%) | 12.65 | 15.70 | 10.87 | 14.16 | 22.60 |
| Return on Networth / Equity (%) | 11.69 | 14.55 | 9.78 | 11.05 | 17.37 |
| Return on Capital Employeed (%) | 15.37 | 18.55 | 12.89 | 14.63 | 22.44 |
| Return On Assets (%) | 9.83 | 12.36 | 8.28 | 9.53 | 15.40 |
| Asset Turnover Ratio (%) | 0.81 | 0.80 | 0.77 | 0.72 | 0.70 |
| Current Ratio (X) | 3.01 | 3.43 | 3.30 | 3.67 | 4.58 |
| Quick Ratio (X) | 1.97 | 2.18 | 2.24 | 2.56 | 3.52 |
| Inventory Turnover Ratio (X) | 5.52 | 1.63 | 1.85 | 1.75 | 1.64 |
| Dividend Payout Ratio (NP) (%) | 30.51 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 25.39 | 0.00 | 0.00 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 69.49 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 74.61 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 92.13 | 109.11 | 73.60 | 106.74 | 125.53 |
| Interest Coverage Ratio (Post Tax) (X) | 60.16 | 76.62 | 48.42 | 70.97 | 89.32 |
| Enterprise Value (Cr.) | 6366.94 | 6886.08 | 4231.47 | 4298.40 | 4791.75 |
| EV / Net Operating Revenue (X) | 3.02 | 3.54 | 2.37 | 2.81 | 3.59 |
| EV / EBITDA (X) | 15.32 | 15.64 | 14.07 | 13.03 | 11.12 |
| MarketCap / Net Operating Revenue (X) | 3.05 | 3.56 | 2.39 | 2.84 | 3.62 |
| Retention Ratios (%) | 69.48 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 2.81 | 3.30 | 2.15 | 2.22 | 2.78 |
| Price / Net Operating Revenue (X) | 3.05 | 3.56 | 2.39 | 2.84 | 3.62 |
| EarningsYield | 0.04 | 0.04 | 0.04 | 0.04 | 0.06 |
After reviewing the key financial ratios for FDC Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 16.39. This value is within the healthy range. It has decreased from 18.58 (Mar 24) to 16.39, marking a decrease of 2.19.
- For Diluted EPS (Rs.), as of Mar 25, the value is 16.39. This value is within the healthy range. It has decreased from 18.58 (Mar 24) to 16.39, marking a decrease of 2.19.
- For Cash EPS (Rs.), as of Mar 25, the value is 19.69. This value is within the healthy range. It has decreased from 21.19 (Mar 24) to 19.69, marking a decrease of 1.50.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 140.11. It has increased from 128.81 (Mar 24) to 140.11, marking an increase of 11.30.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 140.11. It has increased from 128.81 (Mar 24) to 140.11, marking an increase of 11.30.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 129.48. It has increased from 119.34 (Mar 24) to 129.48, marking an increase of 10.14.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 25.52. This value is within the healthy range. It has decreased from 27.04 (Mar 24) to 25.52, marking a decrease of 1.52.
- For PBIT / Share (Rs.), as of Mar 25, the value is 22.22. This value is within the healthy range. It has decreased from 24.58 (Mar 24) to 22.22, marking a decrease of 2.36.
- For PBT / Share (Rs.), as of Mar 25, the value is 21.94. This value is within the healthy range. It has decreased from 24.34 (Mar 24) to 21.94, marking a decrease of 2.40.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 16.39. This value is within the healthy range. It has decreased from 18.74 (Mar 24) to 16.39, marking a decrease of 2.35.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 16.39. This value is within the healthy range. It has decreased from 18.75 (Mar 24) to 16.39, marking a decrease of 2.36.
- For PBDIT Margin (%), as of Mar 25, the value is 19.70. This value is within the healthy range. It has decreased from 22.65 (Mar 24) to 19.70, marking a decrease of 2.95.
- For PBIT Margin (%), as of Mar 25, the value is 17.15. This value is within the healthy range. It has decreased from 20.60 (Mar 24) to 17.15, marking a decrease of 3.45.
- For PBT Margin (%), as of Mar 25, the value is 16.94. This value is within the healthy range. It has decreased from 20.39 (Mar 24) to 16.94, marking a decrease of 3.45.
- For Net Profit Margin (%), as of Mar 25, the value is 12.65. This value exceeds the healthy maximum of 10. It has decreased from 15.70 (Mar 24) to 12.65, marking a decrease of 3.05.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 12.65. This value is within the healthy range. It has decreased from 15.70 (Mar 24) to 12.65, marking a decrease of 3.05.
- For Return on Networth / Equity (%), as of Mar 25, the value is 11.69. This value is below the healthy minimum of 15. It has decreased from 14.55 (Mar 24) to 11.69, marking a decrease of 2.86.
- For Return on Capital Employeed (%), as of Mar 25, the value is 15.37. This value is within the healthy range. It has decreased from 18.55 (Mar 24) to 15.37, marking a decrease of 3.18.
- For Return On Assets (%), as of Mar 25, the value is 9.83. This value is within the healthy range. It has decreased from 12.36 (Mar 24) to 9.83, marking a decrease of 2.53.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.81. It has increased from 0.80 (Mar 24) to 0.81, marking an increase of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 3.01. This value exceeds the healthy maximum of 3. It has decreased from 3.43 (Mar 24) to 3.01, marking a decrease of 0.42.
- For Quick Ratio (X), as of Mar 25, the value is 1.97. This value is within the healthy range. It has decreased from 2.18 (Mar 24) to 1.97, marking a decrease of 0.21.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.52. This value is within the healthy range. It has increased from 1.63 (Mar 24) to 5.52, marking an increase of 3.89.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 30.51. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 30.51, marking an increase of 30.51.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 25.39. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 25.39, marking an increase of 25.39.
- For Earning Retention Ratio (%), as of Mar 25, the value is 69.49. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 69.49, marking an increase of 69.49.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 74.61. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 24) to 74.61, marking an increase of 74.61.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 92.13. This value is within the healthy range. It has decreased from 109.11 (Mar 24) to 92.13, marking a decrease of 16.98.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 60.16. This value is within the healthy range. It has decreased from 76.62 (Mar 24) to 60.16, marking a decrease of 16.46.
- For Enterprise Value (Cr.), as of Mar 25, the value is 6,366.94. It has decreased from 6,886.08 (Mar 24) to 6,366.94, marking a decrease of 519.14.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.02. This value exceeds the healthy maximum of 3. It has decreased from 3.54 (Mar 24) to 3.02, marking a decrease of 0.52.
- For EV / EBITDA (X), as of Mar 25, the value is 15.32. This value exceeds the healthy maximum of 15. It has decreased from 15.64 (Mar 24) to 15.32, marking a decrease of 0.32.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.05. This value exceeds the healthy maximum of 3. It has decreased from 3.56 (Mar 24) to 3.05, marking a decrease of 0.51.
- For Retention Ratios (%), as of Mar 25, the value is 69.48. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 69.48, marking an increase of 69.48.
- For Price / BV (X), as of Mar 25, the value is 2.81. This value is within the healthy range. It has decreased from 3.30 (Mar 24) to 2.81, marking a decrease of 0.49.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.05. This value exceeds the healthy maximum of 3. It has decreased from 3.56 (Mar 24) to 3.05, marking a decrease of 0.51.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in FDC Ltd:
- Net Profit Margin: 12.65%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 15.37% (Industry Average ROCE: 16.15%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 11.69% (Industry Average ROE: 14.71%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 60.16
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.97
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 30.5 (Industry average Stock P/E: 43.06)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 12.65%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | B-8, MIDC Industrial Estate, Aurangabad District Maharashtra 431136 | investors@fdcindia.com www.fdcindia.com |
| Management | |
|---|---|
| Name | Position Held |
| CA. Uday Kumar Gurkar | Chairman & Ind.Director |
| Mr. Mohan A Chandavarkar | Managing Director |
| Mr. Nandan M Chandavarkar | Joint Managing Director |
| Mr. Ameya A Chandavarkar | Executive Director & CEO |
| Mr. Ashok A Chandavarkar | Executive Director |
| Ms. Nomita R Chandavarkar | Non Exe.Non Ind.Director |
| Dr. Mahesh Bijlani | Independent Director |
| Mr. Vijay Maniar | Independent Director |
| Mr. Vijay Nautamlal Bhatt | Independent Director |
| Dr. Charuta Nityanath Mandke | Independent Director |
FAQ
What is the intrinsic value of FDC Ltd?
FDC Ltd's intrinsic value (as of 11 December 2025) is 434.06 which is 2.61% higher the current market price of 423.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 6,885 Cr. market cap, FY2025-2026 high/low of 528/359, reserves of ₹2,415 Cr, and liabilities of 2,886 Cr.
What is the Market Cap of FDC Ltd?
The Market Cap of FDC Ltd is 6,885 Cr..
What is the current Stock Price of FDC Ltd as on 11 December 2025?
The current stock price of FDC Ltd as on 11 December 2025 is 423.
What is the High / Low of FDC Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of FDC Ltd stocks is 528/359.
What is the Stock P/E of FDC Ltd?
The Stock P/E of FDC Ltd is 30.5.
What is the Book Value of FDC Ltd?
The Book Value of FDC Ltd is 149.
What is the Dividend Yield of FDC Ltd?
The Dividend Yield of FDC Ltd is 1.18 %.
What is the ROCE of FDC Ltd?
The ROCE of FDC Ltd is 15.9 %.
What is the ROE of FDC Ltd?
The ROE of FDC Ltd is 11.8 %.
What is the Face Value of FDC Ltd?
The Face Value of FDC Ltd is 1.00.